Abstract 427P
Background
Tumor tissue comprehensive genomic profiling (CGP) identifies molecular targets for precision oncology but with turnaround time (TAT) around one month. We conducted tumor tissue CGP for advanced stage cancer pts from AME using a new and potentially faster tissue-based NGS platform.
Methods
Using DNA-based hybrid capture technology, Guardant360 TissueNext™ reports point mutations and insertions/deletions in 84 genes, fusions for 13 activating partners, amplification (amp) of 20 genes, tumor mutation burden (TMB) score, and microsatellite instability (MSI) status.
Results
Tumor tissue from 412 pts was tested, with success rate 87.3%. Median pt age was 61 years; 54% were male. Median TAT was 15 days (range, 6-127). Mean alteration count/sample was 3.1 (range, 1-29) and mean variant allelic frequency was 19.4% (range, 1.7-88.3). The most profiled cancers included lung (49.4%), colon or rectum (CRC; 9.0%) and breast (6.0%). TP53 (64.6%), EGFR (26.9%) and KRAS (19.0%) were the most mutated genes. EGFR (18.4%), FGFR1 (6.6%) and CCNE1 (6.6%) were the most frequently amplified genes. Fusions were identified in 30 (8.2%) pts and included ALK (2.7%), ROS1 (1.4%) and RET (1.4%). MSI-high was reported for 1.1% and TMB ≥10 mutations/Mb was found in 11.7%. For non-small cell lung cancer (n=176), alterations in genes recommended for testing by the National Comprehensive Cancer Network were mutations in EGFR (53.4%), KRAS (11.5%; 4.3% G12C), ERBB2 (3.7%) and BRAF V600E (1.4%); fusions of ALK (5.5%), ROS1 (2%), RET (2%) and NTRK1/3 (1.7% combined); MET exon14 skipping (1.7%) and MET amp (5.6%). MSI-high and TMB≥10 mutations/Mb were found in 0.7% and 12%, respectively. For CRC (n=33), informative alterations included KRAS mutations (45.4%), BRAF V600E (3%), and ERBB2 amp (6%); 1 patient each had RET and NTRK1 fusions. In breast cancer (n=22), relevant alterations included ERBB2 amp (22%) and mutations in PIK3CA (43%), ESR1 (4.8%), ERBB2 (4.8%) and BRCA1/2 (4.8%).
Conclusions
This analysis of the first tumor samples tested by a new CGP panel in AME demonstrated detection of actionable alterations at the expected frequency with only 15 days median TAT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
N. Sandhir, S. Olsen: Financial Interests, Personal, Full or part-time Employment: Guardant Health. All other authors have declared no conflicts of interest.
Resources from the same session
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract